La chaîne d'options affiche les données clés des options sur actions de Krispy Kreme à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Krispy Kreme..

Krispy Kreme (NASDAQ:DNUT) Stock, Chaîne d'Options

Krispy Kreme

Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S., includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line; International includes operations in the U.K., Ireland, Australia, New Zealand, and Mexico; and Market Development includes franchise operations across the globe, as well as operations in Japan. It derives maximum revenue from U.S. Segment.

Krispy Kreme Inc

A Meta-Analysis of 22 Studies, and Data from the IRIS&#xAE; Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication Reduction with the OMNI&#xAE; Surgical System
MENLO PARK, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=X3pPzilOb8S2OLYwEVVeJ8BbJZdhU5MX0Tom1WQY05CuDb_YTDkhbQbJFfO6Zl8hPVSYlpwF05DBbATk6VxkqN9owLhBQ4m8IbSUKmDw1tGV75lKeCGABMx5WdkcET3b5ogeK_oD2vt0yPdk024MU8elmIYVHSGNIR-h6-_SGfq7TbX0M2cIQXMFY4aiEykgO0BBxMo7jlvxbpFEvCHLR6_KYBBs63LZBSTtMpXYPoEWuDoSfsDmbpGJRXpRkQ13LWFi4xfGhmIAEMOAlk62ZRyYbiv6c6ufRy7nilhqfnXzes90yqNKM7X_kbVOzF0EMPIlqATB8m9c9MkfClhbOznenhT3NM0O4Zbh4aLFwYrQrBwDAwfJBS8AHydoqkaXu67KLc3e9mx4ho0jzUt7XQ==">Sight Sciences, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies&nbsp;intended to transform eye care and improve patients' lives,&nbsp;today announced that multiple presentations on the <a href="https://www.globenewswire.com/Tracker?data=pmEzODEa1Sh2QgAdKg4Xzquiz4yfY4Y2GMY0v6CVBIWcpJnF3Gzlla2U067ee8-VzPgBlHuHoKOLvp9O3lzAmwBShhe6w5H2tT_o-ViBnBNh6BMwFH6jpJnu0vfsLLHM3vnAPALxJWV4FQGTBBshRB3q_KXs9pUHxj7I5snejEYvUHV5pknMZ_yS1RLBCwbmoL8FqD046zk6ujLHRhZZ02aftffQmyqzCi0axOmeouTnPVBCzJfyqfgnLGNArUrvYy5-xqmv5M3y7AongYbjN6k3HkHWEcn_j4mOrYwl6tfXhFvQY_lqRjkViUVWqxXYsrcQtBoPMI81gal_wVATU4WnSHQXyDpSwxS5b8a3OSnmz7bfZeJfdPbeSf6MBIuPavyxZDbJf7ZdYZ7R70rMvA==">OMNI&#xAE; Surgical System</a> ("OMNI") will be presented at the 2025 American Glaucoma Society ("AGS") Annual Meeting in Washington, D.C. from February 26 to March 1. These presentations will showcase new data on the clinical effectiveness and safety of OMNI across diverse patient populations.
The data reinforces the safety and clinical effectiveness of OMNI in treating primary open-angle glaucoma in adult patients. Several of the presentations will feature data curated by Verana Health&#xAE;, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD). The data stems from a partnership between Verana Health and the American Academy of Ophthalmology IRIS&#xAE; Registry (Intelligent Research in Sight), which is one of the largest specialty society clinical data registries in all of medicine and the first comprehensive eye disease clinical registry in the United States.
 &nbsp;

Biotech

News

General

SGHT

Sight Sciences To Present Comprehensive Clinical Data On The OMNI Surgical System At The 2025 American Glaucoma Society Annual Meeting

WIIM

EVER

EverQuote shares are trading higher after the company reported better-than-expected Q4 revenue results and issued Q1 revenue guidance above estimates.

ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) is looking for FY2025 GAAP EPS of $5.37 vs $6.03 analyst estimate..

Guidance

ONEOK Sees FY2025 GAAP EPS $5.37 vs $6.03 Est

Buybacks

HLIO

Helios Technologies Approved $100M Repurchase Program

BWXT

BWX Technologies shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 revenue guidance above estimates.

Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.16 by 12.5 percent. This is a 28.57 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $103.40 million which beat the analyst consensus estimate of $80.55 million by 28.37 percent. This is a 9.85 percent increase over sales of $94.13 million the same period last year.

Earnings

Earnings Beats

BRDG

Bridge Investment Group Q4 Adj $0.18 Beats $0.16 Estimate, Sales $103.40M Beat $80.55M Estimate

JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) reported quarterly earnings of $1.70 per share which missed the analyst consensus estimate of $1.82 by 6.59 percent. This is a 21.43 percent increase over earnings of $1.40 per share from the same period last year. The company reported quarterly sales of $467.60 million which missed the analyst consensus estimate of $489.07 million by 4.39 percent. This is a 5.17 percent increase over sales of $444.60 million the same period last year.

Earnings Misses

JBTM

JBT Marel Q4 Adj $1.70 Misses $1.82 Estimate, Sales $467.60M Miss $489.07M Estimate

LTC Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.66 by 9.09 percent. This is a 26.32 percent increase over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $52.58 million which beat the analyst consensus estimate of $50.07 million by 5.01 percent. This is a 4.76 percent increase over sales of $50.20 million the same period last year.

LTC Properties Q4 FFO $0.72 Beats $0.66 Estimate, Sales $52.58M Beat $50.07M Estimate

VCYT

Veracyte shares are trading lower. The company reported Q4 financial results.

<a href="https://www.sec.gov/Archives/edgar/data/12239/000121390025016617/xslSCHEDULE_13G_X01/primary_doc.xml" title="https://www.sec.gov/Archives/edgar/data/12239/000121390025016617/xslSCHEDULE_13G_X01/primary_doc.xml">https://www.sec.gov/Archives/edgar/data/12239/000121390025016617/xslSCHEDULE_13G_X01/primary_doc.xml</a>

Insider Trades

DOMH

Dominari Holdings 13G Filing Shows Donald J, Trump Jr. Reported A Stake Of 6.71% In The Co As Of February 18, 2025

Topgolf Callaway Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) sees Q1 sales of $1.045 billion-$1.085 billion vs $1.17 billion analyst estimate.

MODG

Topgolf Callaway Brands Sees Q1 Sales $1.045B-$1.085B vs $1.17B Est

CIVI

Civitas Resources Expects FY25 Reducing Capital Invstments Nearly 5% YoY To Range Of $1.8B-$1.9B

Topgolf Callaway Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) sees FY2025 sales of $4.000 billion-$4.185 billion vs $4.32 billion analyst estimate.

Topgolf Callaway Brands Sees FY2025 Sales $4.000B-$4.185B vs $4.32B Est

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.11 by 227.27 percent. This is a 620 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $118.600 million which beat the analyst consensus estimate of $116.765 million by 1.57 percent. This is a 20.78 percent increase over sales of $98.199 million the same period last year.

Veracyte Q4 2024 Adj. EPS $0.36 Beats $0.11 Estimate, Sales $118.600M Beat $116.765M Estimate

Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) sees FY2025 sales of $420.000 million-$435.000 million vs $430.23 million analyst estimate.

AORT

Artivion Sees FY2025 Sales $420.000M-$435.000M vs $430.23M Est

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) is looking for FY2025 GAAP EPS of $1.19-$1.59 vs $1.50 analyst estimate..

Helios Technologies Sees FY2025 GAAP EPS $1.19-$1.59 vs $1.50 Est

Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) reported quarterly sales of $97.31 million which missed the analyst consensus estimate of $100.82 million by 3.48 percent. This is a 3.88 percent increase over sales of $93.67 million the same period last year.

Artivion Q4 Adj EPS $0 Miss $-0.06 Estimate, Sales $97.31M Miss $100.82M Estimate

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) is looking for FY2025 Adj EPS of $2.00-$2.40 vs $2.31 analyst estimate. sees sales of $775.000 million-$825.000 million vs $809.23 million analyst estimate.

Helios Technologies Sees FY2025 Adj EPS $2.00-$2.40 vs $2.31 Est; Sees Sales $775.000M-$825.000M vs $809.23M Est

Clearway Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEN#NYSE">CWEN</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.07 by 57.14 percent. This is a 90.32 percent decrease over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $256.000 million which missed the analyst consensus estimate of $294.080 million by 12.95 percent. This is a 2.81 percent increase over sales of $249.000 million the same period last year.

CWEN

Clearway Energy Q4 2024 GAAP EPS $0.03 Misses $0.07 Estimate, Sales $256.000M Miss $294.080M Estimate

Apple Hospitality REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLE#NYSE">APLE</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.31 by 3.23 percent. This is a 3.23 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $333.04 million which beat the analyst consensus estimate of $329.88 million by 0.96 percent. This is a 6.59 percent increase over sales of $312.46 million the same period last year.

Comments

Krispy Kreme

Krispy Kreme (DNUT) Options

Krispy Kreme (NASDAQ:DNUT) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL